RIDE: Reference-Anchored Inference-Time Diffusion Editing for Scaffold Hopping

Problem

The paper addresses the challenge of scaffold hopping in drug discovery, emphasizing the need for a method that enforces 2D structural novelty while preserving 3D shape. This is particularly relevant in the context of generating novel compounds that maintain desired biological activity. The work is presented as a preprint and has not undergone peer review.

Method

The authors introduce RIDE (Reference-anchored Inference-time Diffusion Editing), which employs a diffusion-based approach to scaffold hopping. The core algorithm recovers the reference diffusion noise trajectory conditioned on the binding pocket and functional groups of the target molecule. It selects the optimal trajectory segment for editing through noise perturbation and implements value-guided scaffold sampling. Notably, RIDE accommodates various reward functions and is capable of preserving 3D similarity even without explicit inclusion of 3D metrics in the reward structure. Specific details regarding the data used and the training compute resources are not disclosed in the paper.

Results

RIDE demonstrates a significant improvement in structural similarity metrics: a 2D similarity improvement of 11.7% and a 3D similarity improvement of 7.3% compared to baseline methods. These results indicate that RIDE effectively enhances both the 2D and 3D characteristics of the generated scaffolds, which is crucial for maintaining biological relevance in drug design.

Limitations

The authors do not report any limitations in their work. However, the lack of specified data and training compute details may hinder reproducibility and practical application in real-world scenarios.

Why it matters

The implications of this work are substantial for downstream applications in drug discovery, particularly in the design of novel compounds with desired pharmacological properties. By improving scaffold hopping techniques, RIDE could facilitate the identification of new drug candidates, thereby accelerating the drug development process and enhancing therapeutic options.